胸腺肽α1结合丝氨酸对耐多药肺结核患者免疫功能及安全性的影响

Effect of Thymosin α1 Combined with Serine on Immune Function and Safety in Patients with Multi Drug Resistant Pulmonary Tuberculosis

目的探讨胸腺肽α1结合丝氨酸对耐多药肺结核患者免疫功能及安全性的影响。方法随机选取2018年3月至2019年3月本溪市第六人民医院收治的90例耐多药肺结核患者作为研究对象,随机分为对照组和观察组,各45例。对照组给予丝氨酸进行治疗,观察组行胸腺肽α1结合丝氨酸进行治疗,比较两组治疗前后免疫功能指标(CD3+T细胞、CD4+T细胞、CD8+T细胞)及不良反应发生情况。结果治疗前,两组CD3+T细胞、CD4+T细胞、CD8+T细胞百分比比较,差异均无统计学意义(t=0.037、0.014、0.036,P=0.970、0.989、0.972);治疗后,观察组CD3+T细胞、CD4+T细胞百分比低于对照组,CD8+T细胞百分比高于对照组,差异均有统计学意义(t=4.681、3.656、2.925,P=0.000、0.000、0.004);观察组不良反应发生率为2.22%,显著低于对照组的22.22%,差异有统计学意义(χ2=8.389,P=0.004)。结论对耐多药肺结核患者进行胸腺肽α1联合丝氨酸治疗,对于患者的免疫功能指标具有明显的改善作用,且不良反应发生率较低,用药安全性高。

Objective To investigate the effect of thymosinα1 combined with serine on immune function and safety in patients with multi drug resistant pulmonary tuberculosis.Methods From March 2018 to March 2019,90 cases of MDR-TB patients in the Sixth People's Hospital of Benxi city were randomly divided into control group(45 cases)and observation group(45 cases).The control group was treated with serine,and the observation group was treated with thymosinα1 combined with serine.The immune function indexes(CD3+T cells,CD4+T cells,CD8+T cells)before and after treatment and the incidence of adverse reactions were compared between the two groups.Results Before treatment,there was no significant difference in the percentages of CD3+T cells,CD4+T cells,CD8+T cells between the two groups(t=0.037,0.014,0.036,P=0.970,0.989,0.972).After treatment,the percentages of CD3+T cells and CD4+T cells in the observation group were lower than those in the control group,and the percentages of CD8+T cells were higher than those in the control group,the differences were statistically significant(t=4.681,3.656,2.925,P=0.000,0.000,0.004).The incidence of adverse reactions in the observation group was 2.22%,which was significantly lower than the 22.22%in the control group,the difference was statistically significant(χ2=8.389,P=0.004).Conclusion Thymosinα1 combined with serine treatment for patients with multi drug resistant pulmonary tuberculosis can significantly improve the immune function of patients,and the incidence of adverse reactions is low,and the medication safety is high.